Quick Takeaways:
- AB Science has received FDA Minor Use in Major Species (MUMS) designation for Masivet in the treatment of canine mast cell tumors. The therapy targets c-kit mutations, a key driver of these tumors, marking a step toward US regulatory advancement
- The MUMS designation, akin to orphan drug status in humans, provides key incentives, including eligibility for grants and up to 7 years of market exclusivity upon approval. While Masivet is already approved and commercialized in Europe, it is yet to receive approval in the US
- AB Science plans to leverage this momentum to expand its animal health footprint globally, with ongoing discussions for distribution across Europe, LATAM, Asia, MENA, and South Africa.
Why It Matters?
MUMS status gives Masivet a clearer US regulatory and commercial path, adding potential 7‑year market exclusivity and grant support on top of its established European use, which should enhance the asset’s value as AB Science courts partners for US entry.
By signaling plans to extend distribution across Europe, LATAM, Asia, MENA, and South Africa, AB Science is trying to turn Masivet into a truly global veterinary oncology franchise, with future US revenues helping subsidize wider R&D and partially self‑fund the company’s broader kinase inhibitor pipeline.
Source: Globenewswire
